Brief: Adalta Says Co & Synthesis Bioventures Partner For Development Of Next Generation Cell-Based Immunotherapies
08/04/2024 02:23
April 8 (Reuters) - Adalta Ltd 1AD.AX :
* CO AND SYNTHESIS BIOVENTURES PARTNER FOR DEVELOPMENT OF
NEXT
GENERATION CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS
Further company coverage: 1AD.AX
((Reuters.Briefs@thomsonreuters.com;))